1. Lucid-MS toxicity studies completed, crucial for IND application. 2. Advancements could lead to Phase 2 trial for multiple sclerosis. 3. Potential breakthrough in MS treatment with the first-in-class Lucid-MS. 4. Company holds 19.86% in Unbuzzd Wellness Inc. with notable royalties. 5. Ongoing litigation and market dynamics may affect future performance.
FAQ
Why Bullish?
The completion of toxicity studies is a significant milestone for QNTM, similar to prior biotech advancements where late-stage trials positively influenced share prices.
How important is it?
The article discusses advancements in a lead drug candidate that may significantly drive QNTM's valuation upward, especially if FDA approval is secured.
Why Long Term?
While immediate price movements may occur upon trial news, long-term growth hinges on successful Phase 2 results, reminiscent of other firms that capitalized on their innovations over time.
Quantum BioPharma (NASDAQ: QNTM) Completes Dosing in Key Toxicity Studies for Lucid-MS
TORONTO, Dec. 23, 2025 (GLOBE NEWSWIRE) – Quantum BioPharma Ltd. (NASDAQ: QNTM), a leading biopharmaceutical company focused on innovative treatments for neurodegenerative and metabolic disorders, has announced the successful completion of oral dosing for its investigational drug, Lucid-21-302 (Lucid-MS). This milestone is a crucial step in the ongoing research and development program aimed at addressing multiple sclerosis (MS).
Completion of 180-Day Toxicity and Toxicokinetics Studies
The recent studies regarding Lucid-MS involved both 180-day toxicity and toxicokinetic assessments. These studies are pivotal in supporting Quantum BioPharma's Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) and are integral to the planning of a forthcoming Phase 2 clinical trial targeting individuals with MS.
Dr. Andrzej Chruscinski, Vice-President of Scientific and Clinical Affairs at Quantum BioPharma, expressed enthusiasm about this crucial advancement: “We are very pleased that dosing is now complete in both 180-day chronic toxicity studies. These studies allow us to advance the Lucid-MS drug development program as they are critical components to the IND application with the FDA.”
Implications for Future Clinical Trials
Following the completion of these toxicity studies, Quantum BioPharma is now two significant steps closer to initiating the Phase 2 trial of Lucid-MS. Anthony Durkacz, Founder and Executive Co-Chairman of Quantum BioPharma, highlighted the importance of these studies: “By completing these 180-day toxicity studies, we are now two important steps closer to initiating the Phase 2 trial of Lucid-MS in people with multiple sclerosis. We are very excited about the potential of this new, first-in-class treatment to prevent disease progression and inhibit demyelination in MS.”
About Quantum BioPharma
Quantum BioPharma (NASDAQ: QNTM) is committed to the development of innovative biotech solutions aimed at treating neurodegenerative and metabolic disorders, along with alcohol misuse disorders. The company’s lead candidate, Lucid-MS, is a patented entity designed to prevent and reverse myelin degradation, a key issue in MS.
In addition to its drug development efforts, Quantum BioPharma retains significant ownership—19.86% as of September 30, 2025—of Unbuzzd Wellness Inc., a subsidiary focusing on health solutions. Furthermore, the agreement with Unbuzzd includes royalty payments of 7% of sales from their product until cumulative payments hit $250 million, at which point the royalty will reduce to 3% indefinitely.
Forward-Looking Statements and Caution
This release contains forward-looking statements that express the company’s predictions, expectations, and plans, which may involve inherent risks and uncertainties. Potential fluctuations in the research and development process, legal actions, and market dynamics may impact the anticipated outcomes.
Investors and interested parties are encouraged to refer to additional information related to Quantum BioPharma at SEDAR+ and the EDGAR section of the SEC's website for comprehensive risk factors and their implications.
Contact Information
For further inquiries, please contact:
- Zeeshan Saeed, Founder, CEO and Executive Co-Chairman of the Board
- Email: Zsaeed@quantumbiopharma.com
- Telephone: (833) 571-1811
- Investor Relations Email: IR@QuantumBioPharma.com
- General Inquiries: info@QuantumBioPharma.com